Organ-Preserving Management of Primary Lynch Syndrome–Associated High-Grade Upper Tract Urothelial Carcinoma Using Gemcitabine–Cisplatin and Pembrolizumab: First Reported Case Worldwide

Read full text Summarise with VIRAT
Authors: Aadhar Jain, Kinju Adhikari, Karthika Rani, Ravi Taori, Deepak Krishnappa, Ankit Joshi, Lingesh Chellaih, S. K. Raghunath
Cited by: 0
References: 7

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Lynch syndrome (LS), caused by germline mismatch-repair mutations, increases the risk of upper tract urothelial carcinoma (UTUC), for which radical nephroureterectomy is the standard treatment. Non-surgical curative management has not been described previously. We report a 48-year-old man with MSH2-associated LS who presented with a 3.5 cm distal ureteric high-grade UTUC. To preserve renal function, multidisciplinary consensus favoured systemic therapy over surgery. He received gemcitabine–cisplatin for six cycles followed by pembrolizumab for two years, achieving complete metabolic response on PET-CT. He remains disease-free at one year. This case demonstrates successful organ-preserving treatment of hereditary UTUC.

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Urinary and Genital Oncology Studies Renal cell carcinoma treatment

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
20 February 2026
Language
EN